Aptamer Sciences Inc
Clinical-stage company developing aptamer-based therapeutics for oncology.
291650 | KO
Overview
Corporate Details
- ISIN(s):
- KR7291650000
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 분당구 판교로228번길 15 3동 301호(삼평동, 판교세븐벤처밸리1), 성남시
- Website:
- https://aptsci.com/en/
- Sector:
- Manufacturing
Description
Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-27 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.6 KB | ||
| 2024-11-27 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.1 KB | ||
| 2024-11-26 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 121.7 KB | ||
| 2024-11-22 00:00 |
[기재정정]증권신고서(지분증권) (2024.11)
|
Korean | 2.4 MB | ||
| 2024-11-14 00:00 |
분기보고서 (2024.09)
|
Korean | 870.7 KB | ||
| 2024-11-14 00:00 |
[기재정정]증권신고서(지분증권) (2024.11)
|
Korean | 3.1 MB | ||
| 2024-11-06 00:00 |
투자설명서
|
Korean | 2.5 MB | ||
| 2024-11-01 00:00 |
[기재정정]증권신고서(지분증권) (2024.11)
|
Korean | 3.4 MB | ||
| 2024-10-28 00:00 |
유상증자1차발행가액결정
|
Korean | 8.4 KB | ||
| 2024-10-28 00:00 |
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 38.7 KB | ||
| 2024-10-28 00:00 |
[발행조건확정]증권신고서(지분증권)
|
Korean | 536.9 KB | ||
| 2024-10-28 00:00 |
권리락 (유상증자)
|
Korean | 3.5 KB | ||
| 2024-10-25 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정) (압타머-약물접합체(ApDC) 고형암 치료제 AST-201의 국내 제…
|
Korean | 11.3 KB | ||
| 2024-10-22 00:00 |
[기재정정]증권신고서(지분증권) (2024.11)
|
Korean | 3.4 MB | ||
| 2024-10-21 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 9.8 KB |
Automate Your Workflow. Get a real-time feed of all Aptamer Sciences Inc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aptamer Sciences Inc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aptamer Sciences Inc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
